Collectively, the results demonstrated that selectively targeting the TGF-β/Smad signaling pathway with galunisertib effectively prevents GC-LM by inhibiting fibrotic PMN formation and attenuating the migration and invasion of metastatic GC cells in the liver. The gene discussed is TGFB1; the disease is lymphangioma.